AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 19, 2017 | $115,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Oct 19, 2017 | $130,000 | Replaced |
| 3rd Quarter - Amendment | Jul 18, 2018 | $240,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Agriculture, Rural Development, Food and Drug Administration, and related Agencies Appropriations seeking Food and Drug Administration funding. Discussion with the House on opioid addiction.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH M HILL | — |
| JILLANNE SCHULTE | — |
| CHRISTOPHER J TOPOLESKI | — |
Medicare/Medicaid MMM
Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH M HILL | — |
| JILLANNE SCHULTE | — |
| CHRISTOPHER J TOPOLESKI | — |
Pharmacy PHA
Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH M HILL | — |
| JILLANNE SCHULTE | — |
| CHRISTOPHER J TOPOLESKI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.